⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Large Cap · Disruption threat: MEDIUM
Becton Dickinson integrates AI into diagnostics, medication management, and smart device platforms, with BD Synapsys and AI-driven infusion systems representing key product-level deployments. AI exposure remains steady with incremental advances in clinical decision support and operational analytics, but no transformative revenue-generating AI breakthrough has emerged since prior assessment.
Becton Dickinson is a global medical technology company specializing in diagnostics, medication management, and smart device platforms. With an overall AI score of 62/100, BDX occupies a measured but credible position in healthcare AI, deploying machine learning across clinical workflows and operational systems without yet achieving a transformative AI-driven revenue inflection. Product AI Integration (65/100) and Internal AI Use (65/100) are the strongest contributors to BDX's score, reflecting meaningful real-world deployments including BD Synapsys for diagnostic informatics, AI-assisted specimen processing, and AI-driven infusion and dispensing systems. R&D AI Investment (60/100) indicates sustained but not aggressive commitment to next-generation capabilities. Revenue from AI (35/100) is notably the weakest dimension, confirming that current AI integrations enhance existing products rather than generate discrete, attributable revenue streams. AI Infrastructure (50/100) suggests backend capabilities remain a work in progress. A medium disruption threat implies BDX faces meaningful but manageable competitive pressure. Rivals investing more aggressively in autonomous diagnostics or AI-native clinical platforms could erode BDX's positioning in lab automation and medication management over a three-to-five year horizon. The key opportunity lies in monetizing BD Synapsys and expanding AI-driven clinical decision support into higher-acuity settings, which could meaningfully lift the revenue attribution score and differentiate BDX in an increasingly AI-competitive medtech landscape.
Full interactive analysis at RankVis.io